A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Multi-Site Study to Evaluate the Clinical Equivalence of Lubiprostone 24mcg Capsules (Anchen Pharmaceuticals, Inc.) with XXX (lubiprostone) 24mcg Capsules (Sucampo Pharmaceuticals, Inc.) in the Treatment of Chronic Idiopathic Constipation.
A double blind, randomized, placebo controlled, parallel group, multisite study to evaluate the clinical equivalance of XXX 1% gel (anchen pharmaceuticals) with XXX gel (Novartis) in patients with OA of Knee.
A phase 3 randomized, double blind, placebo controlled trial of XXX for the treatment of IDA.
A phase 3 randomized, double blind, placebo controlled trial of XXX for the episodic treatment of IDA.
An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in OpioidInduced Constipation (OIC) in Patients with Non-Cancer-Related Pain.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC).
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in the Treatment of Patients With DiarrheaPredominant Irritable Bowel Syndrome.
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of XXX for the treatment of Opioid -Induced Constipation in Adults Taking Opiod Therapy for Chronic Non-.Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, phase 3 study to evaluate the efficacy and safety and Tolerability of XXX IN THE TREATMENT OF PATIENTS WITH DiarrheaPredominant Irritable Bowel Syndrome (IBS-d)…
A Phase 3, Randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of XXX when added to Metformin in subjects with Type 2 Diabetes Mellitus
A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of XXX when added to YYY in subjects with Type 2 Diabetes Mellitus
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of (drug) Monotherapy in Subjects with type 2 Diabetes Mellitus.
A randomized double blind, double dummy, placebo controlled, active controlled, parallel group, multi center trial of XXX controlled release tablets to assess the analgesic efficacy (compared to placebo) and the management of OIC (compared to XXX controlled release tablets) in opioid experienced subjects with uncontrolled moderate to severe chronic low back pain and a history of OIC who require around the clock opioid therapy.
A randomized, double blind, placebo controlled study to assess the efficacy and safety of NKTR-118 in relieving opioid induced constipation in patients with cancer related pain
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC).
A confirmatory, placebo controlled, randomized, double blind, single dummy, parallel group, ratio finding study in constipated pain patients to establish an optimal XXX ratio with an improved bowel function and a comparable analgesic efficacy compared to YYY alone.
A phase 3 randomized, double blind, placebo controlled, parallel group, multi center study to evaluate the safety and efficacy of XXX induction therapy in subjects with moderately to severely active Crohn's disease who have failed or Are intolerant to TNF antagonist therapy.
A phase 3 randomized, double blind, placebo controlled, parallel group, multi center study to evaluate the safety and efficacy of XXX induction therapy in subjects with moderately to severely active Crohn's disease.
A randomized, double blind, placebo controlled, multi-center trial with an enriched study design to assess the efficacy and safety of xxx/ xxx control released tablets compared to placebo in opioid experienced subjects with moderate to severe pain due to chronic low back pain who require around the clock opioid therapy.
A phase 1b exploratory study to access the safety, Tolerability colonic tissue exposure and anti-inflammatory effects of two different doses of SRT 2104 in subjects with mild to moderate ulcerative colitis
Longitudinal study of patients with Opioid Induced Constipation
A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the long-term safety and tolerability of CB-5945 for the treatment of opioid-induced constipation in adults taking opioid therapy for chronic non cancer pain
A phase 3 double blind placebo controlled, multi-center, randomized withdrawal study to evluate the analgesic efficacy, safety and tolerability of XXX Bupernorphine in opioid experienced subjects with moderate to severe chronic low back pain requiring around the clock opioid analgesia for an extended period of time
A phase 3 double blind placebo controlled, multi-center, randomized withdrawal study to evluate the analgesic efficacy, safety and tolerability of XXX in opioid naive subjects with moderate to severe chronic low back pain requiring around the clock opioid analgesia for an extended period of time
A phase 3 open label, long term study to evaluate the safety, tolerability and analgesic efficacy of XXX in subjects with moderate to severe chronic pain requiring continuous around the clock opioid analgesia for an extended period of time
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and efficacy of Addition of XXX compared with the addition of YYY in subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic control of Metformin
A Multi-center Double-blind, Randomized, Controlled Trial to Evaluate the Effectiveness and Safety of Co-administered XXX and YYY (IA) Injections versus Placebo IA Injections in Patients with Moderate-to-Severe Pain Associated with Osteoarthritis of the Knee
A phase 3 randomized 12 week, double blind, placebo controlled study to assess the safety and efficacy of study drug in patients with chronic idiopathic constipation and an open label extension (OLE) long-term safety and tolerability study of study drug in patients with chronic idiopathic constipation.
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in Adolescent Patients with Major Depressive Disorder
An Open Label Extension (OLE), Long-term Safety and tolerability study of XXX in patients with Chronic Idiopathic Constipation (CIC)
A phase 2b, randomized, double blind, placebo controlled, parallel group, multi center study of XXX administered as monotherapy and in combination with YYY for the treatment of acute uncomplicated seasonal Influenza A in adult subjects.
Prospective observational study of patients with Polycythemia in US clinical practices
Real-world study evaluating XXX Treatment patterns and outcomes in patients with Atrial Fibrillation: Wave 2
A multicenter, randomized, double blind, parallel group study of CNTO136 administered subcutaneaously as Monotherapy compared with XXX monotherapy in subjects with active Rheumatoid Arthritis
A randomized, double blind, placebo controlled, parallel group, multi center, phase 3 study to evaluate the long term safety of XXX for the treatment of OIC in subjects with Non-malignant chronic pain receiving opioid therapy.
A phase 3 double blind, placebo controlled study to assess the efficacy, safety and tolerability of NKTR-181 in opioid naiive subjects with moderate to severe chronic low back pain
A phase e multi center, open label 52 week study to evaluate the long term safety and tolerability of NKTR-181 in subjects with moderate to severe chronic non-cancer pain
A randomized, double blind, parallel group, mulit center, placebo controlled, dose ranging study to evaluate the glycemic effects, safety, and tolerability of XXX delayed-release in subjects with type 2 diabetes mellitus
An open label, long term safety study of XXX administered to adult patients with irritable bowel syndrome with constipation or chronic idiopathic constipation
A Phase 3 randomized, double blind, placebo and active controlled, multi center, parallel group study of the analgesic efficacy and safety of XXX in adult subjects with chronic low back pain.
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study with a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of XXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial with a 28-week Extension to Evaluate the Efficacy and Safety of XXX Coadministered with YYY Compared to ZZZ in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin with or without AAA therapy
A Randomied double blind, placebo and active controlled study of XXX in subjects with pain associated with Fibromyalgia and an open label extension study of XXX for 52 weeks in pain associated with Fibromyalgia.